Our findings underscore the potential of emodin as a naturally sourced combination partner for PPARγ agonists, offering a clinically actionable strategy to overcome weight gain-associated discontinuation in the pharmacotherapy of type 2 diabetes with obesity comorbidity. This evidence concerns the gene PPARG and type 2 diabetes mellitus.